

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2019/210081 A2

(43) International Publication Date
31 October 2019 (31.10.2019)

(51) International Patent Classification:
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2019/029163

(22) International Filing Date:
25 April 2019 (25.04.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/662,817 26 April 2018 (26.04.2018) US

(71) Applicant: **BAYLOR COLLEGE OF MEDICINE**
[US/US]; One Baylor Plaza, Houston, TX 77030 (US).

(72) Inventors: **MAMONKIN, Maksim**; 8401 Rayleine Drive,
Pearland, TX 77584 (US). **BRENNER, Malcolm, K.**; 4802
Willow, Bellaire, TX 77401 (US). **MO, Feiyan**; C/o Baylor
College of Medicine, One Baylor Plaza, Houston, TX 77030
(US).

(74) Agent: **SISTRUNK, Melissa, L.** et al.; Norton Rose Ful-
bright Us LLP, 1301 McKinney, Suite 5100, Houston, TX
77010-3095 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*

(54) Title: AUTO/ALLO-IMMUNE DEFENSE RECEPTORS FOR THE SELECTIVE TARGETING OF ACTIVATED
PATHOGENIC T CELLS AND NK CELLS

(57) Abstract: Embodiments of the disclosure concern engineered auto/allo-immune defense receptor (ADR)-expressing T cells that selectively target activated T cells, including pathogenic T cells, to incapacitate them. The chimeric receptors comprise moieties for targeting 4-1BB, OX40, and CD40L, for example, whose expression is indicative of activated T cells. In particular embodiments, there are methods of preventing or treating conditions associated with activated T cells using adoptive T-cell transfer of cells encoding the ADRs.



WO 2019/210081 A2